Catalyst Pharmaceuticals, Inc. (CPRX) Given a $6.00 Price Target by Piper Jaffray Companies Analysts
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) received a $6.00 price objective from Piper Jaffray Companies in a research note issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price would suggest a potential upside of 107.61% from the company’s previous close.
Separately, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Monday, May 22nd.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded up 0.70% during midday trading on Monday, hitting $2.89. 584,440 shares of the company were exchanged. Catalyst Pharmaceuticals has a one year low of $0.73 and a one year high of $3.20. The company has a 50-day moving average of $2.80 and a 200 day moving average of $1.91. The company’s market capitalization is $242.14 million.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). On average, equities research analysts expect that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. Oxford Asset Management boosted its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares in the last quarter. Royal Bank of Canada purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at $117,000. Goldman Sachs Group Inc. boosted its stake in Catalyst Pharmaceuticals by 265.1% in the first quarter. Goldman Sachs Group Inc. now owns 101,855 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 73,958 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at $149,000. 29.79% of the stock is owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.